161 related articles for article (PubMed ID: 36624015)
1. Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion.
Zhang Y; Nguyen L; Lu CM; Wang E; Lauw MIS; Ball S; Dong N; Moscinski L; Chan O; Yun S; Sallman D; Sokol L; Shah B; Knepper T; Lancet J; Komrokji R; Padron E; Kuykendall A; Zhang L
Clin Lymphoma Myeloma Leuk; 2023 Mar; 23(3):e150-e163. PubMed ID: 36624015
[TBL] [Abstract][Full Text] [Related]
2. A
Venable ER; Gagnon MF; Pitel BA; Palmer JM; Peterson JF; Baughn LB; Hoppman NL; Greipp PT; Ketterling RP; Patnaik MS; Kelemen K; Xu X
Cold Spring Harb Mol Case Stud; 2023 Feb; 9(1):. PubMed ID: 36627146
[TBL] [Abstract][Full Text] [Related]
3. Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort.
Metzgeroth G; Steiner L; Naumann N; Lübke J; Kreil S; Fabarius A; Haferlach C; Haferlach T; Hofmann WK; Cross NCP; Schwaab J; Reiter A
Leukemia; 2023 Sep; 37(9):1860-1867. PubMed ID: 37454239
[TBL] [Abstract][Full Text] [Related]
4. Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.
Gerds AT; Gotlib J; Bose P; Deininger MW; Dunbar A; Elshoury A; George TI; Gojo I; Gundabolu K; Hexner E; Hobbs G; Jain T; Jamieson C; Kuykendall AT; McMahon B; Mohan SR; Oehler V; Oh S; Pardanani A; Podoltsev N; Ranheim E; Rein L; Salit R; Snyder DS; Stein BL; Talpaz M; Thota S; Vachhani P; Wadleigh M; Walsh K; Ward DC; Bergman MA; Sundar H
J Natl Compr Canc Netw; 2020 Sep; 18(9):1248-1269. PubMed ID: 32886902
[TBL] [Abstract][Full Text] [Related]
5. Myeloid neoplasms with eosinophilia.
Reiter A; Gotlib J
Blood; 2017 Feb; 129(6):704-714. PubMed ID: 28028030
[TBL] [Abstract][Full Text] [Related]
6. Rare and potentially fatal - Cytogenetically cryptic TNIP1::PDGFRB and PCM1::FGFR1 fusion leading to myeloid/lymphoid neoplasms with eosinophilia in children.
Berking AC; Flaadt T; Behrens YL; Yoshimi A; Leipold A; Holzer U; Lang P; Quintanilla-Martinez L; Schlegelberger B; Reiter A; Niemeyer C; Strahm B; Göhring G
Cancer Genet; 2023 Apr; 272-273():29-34. PubMed ID: 36657267
[TBL] [Abstract][Full Text] [Related]
7. Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3.
Walz C; Erben P; Ritter M; Bloor A; Metzgeroth G; Telford N; Haferlach C; Haferlach T; Gesk S; Score J; Hofmann WK; Hochhaus A; Cross NC; Reiter A
Blood; 2011 Aug; 118(8):2239-42. PubMed ID: 21705501
[TBL] [Abstract][Full Text] [Related]
8. T cell phenotype and lack of eosinophilia are not uncommon in extramedullary myeloid/lymphoid neoplasms with ETV6::FLT3 fusion: a case report and review of the literature.
Schoelinck J; Gervasoni J; Guillermin Y; Beillard E; Pissaloux D; Chassagne-Clement C
Virchows Arch; 2023 Nov; ():. PubMed ID: 37985498
[TBL] [Abstract][Full Text] [Related]
9. Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes: A workshop report with focus on novel entities and a literature review including paediatric cases.
Saft L; Kvasnicka HM; Boudova L; Gianelli U; Lazzi S; Rozman M
Histopathology; 2023 Dec; 83(6):829-849. PubMed ID: 37551450
[TBL] [Abstract][Full Text] [Related]
10. Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes.
Schwaab J; Naumann N; Luebke J; Jawhar M; Somervaille TCP; Williams MS; Frewin R; Jost PJ; Lichtenegger FS; La Rosée P; Storch N; Haferlach T; Horny HP; Fabarius A; Haferlach C; Burchert A; Hofmann WK; Cross NCP; Hochhaus A; Reiter A; Metzgeroth G
Am J Hematol; 2020 Jul; 95(7):824-833. PubMed ID: 32279331
[TBL] [Abstract][Full Text] [Related]
11. A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia.
Chung A; Hou Y; Ohgami RS; Von Gehr A; Fisk DG; Roskin KM; Li X; Gojenola L; Bangs CD; Arber DA; Fire AZ; Cherry AM; Zehnder JL; Gotlib J; Merker JD
Cancer Genet; 2017 Oct; 216-217():10-15. PubMed ID: 29025582
[TBL] [Abstract][Full Text] [Related]
12. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.
Patterer V; Schnittger S; Kern W; Haferlach T; Haferlach C
Ann Hematol; 2013 Jun; 92(6):759-69. PubMed ID: 23400675
[TBL] [Abstract][Full Text] [Related]
13. ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia presenting in an infant: an entity distinct from JMML.
Spitzer B; Dela Cruz FS; Ibanez Sanchez GD; Zhang Y; Xiao W; Benayed R; Markova A; Rodriguez-Sanchez MI; Bouvier N; Roshal M; Kung AL; Shukla N
Blood Adv; 2021 Apr; 5(7):1899-1902. PubMed ID: 33792628
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of Tyrosine Kinase Inhibitor Combined with Decitabine, Homoharringtonine, Interferon in the Maintenance Therapy of Blast Phase Chronic Myeloid Leukemia].
Li ZY; Zhao HF; Zhang YL; Song YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):649-653. PubMed ID: 37356921
[TBL] [Abstract][Full Text] [Related]
16. The diagnostic challenges and clinical course of a myeloid/lymphoid neoplasm with eosinophilia and
Lee WY; Pfau RB; Choi SM; Yang J; Xiao H; Putnam EM; Ryan RJ; Bixby DL; Shao L
Cold Spring Harb Mol Case Stud; 2020 Apr; 6(2):. PubMed ID: 32238402
[TBL] [Abstract][Full Text] [Related]
17. FIP1L1-PDGFRA fusion gene in T-lymphoblastic lymphoma: A case report.
Ali S; Al-Qattan Y; Awny W; Hamadah A; Pinto K; AlShemmari S
Cancer Rep (Hoboken); 2023 Jan; 6(1):e1769. PubMed ID: 36517458
[TBL] [Abstract][Full Text] [Related]
18. Sustained Response to Imatinib in a Pediatric Patient with Concurrent Myeloproliferative Disease and Lymphoblastic Lymphoma Associated with a CCDC88C-PDGFRB Fusion Gene.
Bielorai B; Leitner M; Goldstein G; Mehrian-Shai R; Trakhtenbrot L; Fisher T; Marcu V; Yalon M; Schiby G; Barel O; Cal N; Golan H; Toren A
Acta Haematol; 2019; 141(2):119-127. PubMed ID: 30726835
[TBL] [Abstract][Full Text] [Related]
19. Impact of frontline treatment approach on outcomes of myeloid blast phase CML.
Saxena K; Jabbour E; Issa G; Sasaki K; Ravandi F; Maiti A; Daver N; Kadia T; DiNardo CD; Konopleva M; Cortes JE; Yilmaz M; Chien K; Pierce S; Kantarjian H; Short NJ
J Hematol Oncol; 2021 Jun; 14(1):94. PubMed ID: 34130720
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
